Non-imidazole histamine H3 ligands, Part IV: SAR of 1-[2-thiazol-5-yl-(2-aminoethyl)]-4-n-propylpiperazine derivatives

European Journal of Medicinal Chemistry

Volumn 44, Issue 4, 2009, Pages 1674-1681

  Frymarkiewicz, Anna ^a   Walczyński, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

1 2 Thiazol 5 yl (2 aminoethyl) 4 n propylpiperazine derivatives; H3 Antagonists; Histamine H3 receptor

Indexed keywords

1 [2 THIAZOL 5 YL (2 METHYL 2 PHENYLPROPYLAMINOETHYL)] 4 PROPYLPIPERAZINE; ALIPHATIC AMINE; ALKYL GROUP; AMIDE; HISTAMINE H1 RECEPTOR; HISTAMINE H3 RECEPTOR ANTAGONIST; PIPERAZINE DERIVATIVE; THIOPERAMIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; EVOKED RESPONSE; GUINEA PIG; ILEUM; IN VITRO STUDY; JEJUNUM; MALE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; GUINEA PIGS; HISTAMINE H1 ANTAGONISTS; HISTAMINE H3 ANTAGONISTS; IMIDAZOLES; JEJUNUM; MALE; PIPERAZINES; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 61349092868     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.09.019     Document Type: Article

References (36)

1. Arrang J.-M., Garbarg M., and Schwartz J.-C. Nature (London) 302 (1983) 832-837
2. Arrang J.-M., Garbarg M., and Schwartz J.-C. Neuroscience 15 (1985) 553-562
3. Arrang J.-M., Garbarg M., and Schwartz J.-C. Neuroscience 23 (1987) 149-157
4. Clapham J., and Kilpatrick G.-J. Br. J. Pharmacol. 107 (1992) 919-923
5. Yokatoni K., Murakami Y., Okada S., Wang M., and Nakamura K. Eur. J. Pharmacol. 392 (2000) 23-29
6. Schlicker E., Fink K., Detzner M., and Göthert M. J. Neural Transm. Gen. Sect. 93 (1993) 1-10
7. Schlicker E., Schunack W., and Göthert M. Naunyn-Schmiedeberg's Arch. Pharmacol. 342 (1990) 497-501
8. Schlicker E., Betz R., and Göthert M. Naunyn-Schmiedeberg's Arch. Pharmacol. 337 (1988) 588-590
9. Brown R.E., and Reymann K.G. J. Physiol. 496 (1996) 175-184
10. Matsubara T., Moskowitz M.A., and Huang Z. Eur. J. Pharmacol. 224 (1992) 23-29
11. Lovenberg T.W., Roland B.L., Wilson S.J., Jiang X., Pyati J., Huvar A., Jackson M.R., and Erlander M.G. Mol. Pharmacol. 55 (1999) 1101-1107
12. Tradivel-Lacomb J., Rouleau A., Heron A., Morisset S., Pillot C., Cochois V., Schwartz J.-C., and Arrang J.-M. Neuroreport 11 (2000) 755-759
13. Lovenberg T.W., Pyati J., Chang H., Wilson S.J., and Erlander M.G. J. Pharmacol. Exp. Ther. 293 (2000) 771-778
14. Morisset S., Rouleau A., Ligneau X., Gbahou F., Tradivel-Lacomb J., Stark H., Schunack W., Ganellin C.R., Schwartz J.-C., and Arrang J.-M. Nature 408 (2000) 860-864
15. Morisset S., Sasse A., Gbahou F., Heron A., Ligneau X., Tradivel-Lacomb J., Schwartz J.-C., and Arrang J.-M. Biophys. Res. Commun. 280 (2001) 75-80
16. Drutel G., Peitsaro N., Karlstedt K., Wieland K., Smith M.J., Timmerman H., Panula P., and Leurs R. Mol. Pharmacol. 59 (2001) 1-8
17. Wellendorf P., Goodman M.W., Burstein E.S., Nash N.R., Brann M.R., and Weiner D.M. Neuropharmacology 42 (2002) 929-940
18. Stark H., Schlicker E., and Schunack W. Drugs Future 21 5 (1996) 507-520
19. Van der Goot H., and Timmerman H. Eur. J. Med. Chem. 35 (2000) 5-20
20. Arrang J.-M., Garbarg M., Lancelot J.-C., Lecomte J.-M., Pollard H., Robba M., Schunack W., and Schwartz J.-C. Nature 327 (1987) 117-123
21. Van der Goot H., Schepers M.J.-P., Sterk G.-J., and Timmerman H. Eur. J. Med. Chem. 27 (1992) 511-517
22. Wullf B., Hastrup S., and Rimvall K. Eur. J. Pharmacol. 453 (2002) 33-41
23. Wieland K., Bongeres G., Yamamoto Y., Hashimoto T., Yamatodani A., Menge W.M.P.B., Timmerman H., Lovenberg T.W., and Leurs R. J. Pharm. Exp. Ther. 299 (2001) 908-914
24. Lin J.H., and Lu A.Y.H. Clin. Pharmacokinet. 35 (1998) 361-390
25. Ganellin C.R., Lurquin F., Piripitsi A., Arrang J.-M., Garbarg M., Ligneau X., Schunack W., and Schwartz J.-C. Arch. Pharm. Med. Chem. 331 (1998) 395-404
26. Cowart M., Altenbach R., Black L., Faghih R., Zhao C., and Hanckok A.A. Mini-Rev. Med. Chem. 4 (2004) 979-992
27. Celanire S., Wijtmans M., Talaga P., Leurs R., and de Esch I.J.P. Drug Discov. Today 10 (2005) 1613-1627
28. Apelt J., Ligneau X., Pertz H.H., Arrang J.-M., Ganellin C.R., Elz S., Schwartz J.-C., Schunack W., and Stark H. J. Med. Chem. 45 (2002) 1128-1141
29. Walczyński K., Guryn R., Zuiderveld O.P., and Timmerman H. Il Farmaco 54 (1999) 684-694
30. Walczyński K., Guryn R., Zuiderveld O.P., and Timmerman H. Arch. Pharm. Pharm. Med. Chem. 332 (1999) 389-398
31. Walczyński K., Zuiderveld O.P., and Timmerman H. Eur. J. Med. Chem. 40 (2005) 15-23
32. Vollinga R.C., Zuiderveld O.P., Scheerens H., Bast A., and Timmerman H. Meth. Find. Exp. Clin. Pharmacol. 105 (1992) 747-751
33. Eriks J.Ch., van der Goot H., Geert J.S., and Timmerman H. J. Med. Chem. 35 (1992) 3239-3246
34. Van Es A., and Stevens W. Rec. Trav. Chim. Pays-Bas 84 (1965) 704-709
35. Collins R.F., and Davis M. J. Chem. Soc. (1961) 1863-1879
36. Arunlakshana O., and Schild H.O. Br. J. Pharmacol. 14 (1959) 48-55